Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics

Viking Therapeutics, Inc. (VKTX): $6.28

-0.12 (-1.88%)

POWR Rating

Component Grades













VKTX Stock Price Chart Interactive Chart >

Price chart for VKTX

VKTX Price/Volume Stats

Current price $6.28 52-week high $10.09
Prev. close $6.40 52-week low $4.95
Day low $6.09 Volume 951,816
Day high $6.42 Avg. volume 1,214,465
50-day MA $5.87 Dividend yield N/A
200-day MA $6.32 Market Cap 490.47M

Viking Therapeutics, Inc. (VKTX) Company Bio

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.

VKTX Latest News Stream

Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream

Loading social stream, please wait...

View Full VKTX Social Stream

Latest VKTX News From Around the Web

Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

Why Viking Therapeutics Stock Briefly Popped Today

What happened Shares of the developmental-stage biotech Viking Therapeutics (NASDAQ: VKTX) jumped by as much as 11.2% in pre-market action Thursday morning. The company's shares perked up in response to an intriguing top-line readout for the experimental X-linked adrenoleukodystrophy (X-ALD) drug dubbed VK0214 in a phase 1 trial.

Yahoo | June 17, 2021

Viking Therapeutics' VK0214 Shows Encouraging Safety, Tolerability Profile In Healthy Volunteers

Viking Therapeutics Inc (NASDAQ: VKTX) has announced results from its Phase 1 trial of VK0214 in healthy volunteers. VK0214 demonstrated encouraging safety and tolerability at all doses, as well as a predictable pharmacokinetic (PK) profile. No serious adverse events were reported, and no treatment or dose-related trends were observed for vital signs, gastrointestinal effects, cardiovascular measures, or physical examinations. VK0214 demonstrated dose-dependent exposures, no evidence of accumula

Yahoo | June 17, 2021

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available small molecule thyroid receptor beta (TRβ) agonist in development for the potential treatment for X-linked adrenoleukodystrophy (X-ALD). In this study, VK02

Yahoo | June 17, 2021

Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences.

Yahoo | June 10, 2021

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB ) Nuvation Bio Inc. (NYSE: NUVB ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) PLx Pharma Inc. (NASDAQ: PLXP ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 26) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Axcella Health Inc. (NASDAQ: AXLA ) Black Diamond Therapeutics, Inc. (NASDAQ: BDTX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Coherus BioSciences, Inc. (NASDAQ: CHRS ) Evofem Biosciences, Inc. (NASDAQ: EVFM ) Impel NeuroPharma, Inc. (NASDAQ: IMPL ) IMV Inc. (NASDAQ: IMV ) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT...

Benzinga | May 27, 2021

Read More 'VKTX' Stories Here

VKTX Price Returns

1-mo 6.26%
3-mo -0.16%
6-mo -2.18%
1-year -16.49%
3-year -48.61%
5-year 372.18%
YTD 11.55%
2020 -29.80%
2019 4.84%
2018 88.42%
2017 241.18%
2016 -65.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7311 seconds.